Aytu BioPharmaAYTU +0.47%40 Days Inventory is 152.80 as of Mar. 2026, which is 30% below its 10-year median of 219.84. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 918 Drug Manufacturers companies, Aytu BioPharma ranks worse than 55.99% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Aytu BioPharma's Average Total Inventories for the
three
months ended in Mar. 2026 was $8.06 Mil. Aytu BioPharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $4.81 Mil.
Hence, Aytu BioPharma's Days Inventory for the
three
months ended in Mar. 2026 was 152.80.
The historical rank and industry rank for Aytu BioPharma's Days Inventory or its related term are showing as below:
AYTU'
s Days Inventory Range Over the Past 10 Years
Min: 102.26 Med: 219.84 Max: 273.1
Current: 178.35
During the past 13 years, Aytu BioPharma's highest Days Inventory was 273.10. The lowest was 102.26. And the median was 219.84.
AYTU's Days Inventory is ranked worse than 55.99% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs AYTU: 178.35
Aytu BioPharma's Days Inventory
declined
from Mar. 2025 (178.94) to Mar. 2026 (152.80).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aytu BioPharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.60.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aytu BioPharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.65.
Aytu BioPharma (NAS:AYTU) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Aytu BioPharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aytu BioPharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Aytu BioPharma Days Inventory Related Terms
Aytu BioPharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AYTU vs TXMD, CPHI, RMTI: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a Days Inventory of 152.80 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aytu BioPharma and its competitors. This is 30% below median its historical median of 219.84. Over the past decade, Aytu BioPharma's Days Inventory has ranged from 102.26 to 273.10. According to the industry distribution chart, Aytu BioPharma ranks #514 out of 918 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is Aytu BioPharma's Days Inventory too high?
Aytu BioPharma's current Days Inventory of 152.80 is 30% below median its 10-year median of 219.84. Over the past 10 years, this metric has ranged from a low of 102.26 to a high of 273.10. The Drug Manufacturers industry median Days Inventory is 164.43. Aytu BioPharma's value of 152.80 is 7.1% below this industry median. Based on the distribution chart, Aytu BioPharma ranks #514 out of 918 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Days Inventory compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #514 out of 918 companies for Days Inventory. This places Aytu BioPharma in the lower half of its industry. The industry median Days Inventory is 164.43. Aytu BioPharma's value of 152.80 is 7.1% below this benchmark. Historically, Aytu BioPharma's own Days Inventory has ranged from 102.26 to 273.10 over the past decade. While the company's 10-year median is 219.84 vs. the industry median of 164.43, Aytu BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current Days Inventory of 152.80 is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Days Inventory is 152.80, which is 30% below median its own 10-year median of 219.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.16 — trading 157.1% above its estimated fair value. The current Days Inventory is 152.80, which is 30% below median its 10-year median of 219.84 and 7.1% below the Drug Manufacturers industry median of 164.43. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Days Inventory is 152.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.16 is trading 157.1% above its estimated GF Value™ of $0.84.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Days Inventory: 152.80 (30% below median its 10-year median of 219.84)
GF Value™: $0.84 vs. price of $2.16 (157.1% above fair value)
Industry Position: 7.1% below the Drug Manufacturers median (#514 of 918)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for AYTU
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
